Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Senti Biosciences (SNTI) Return on Sales (2021 - 2024)

Senti Biosciences has reported Return on Sales over the past 4 years, most recently at 64.09% for Q2 2024.

  • Quarterly results put Return on Sales at 64.09% for Q2 2024, up 7057.0% from a year ago — trailing twelve months through Jun 2024 was 64.09% (up 6979.0% YoY), and the annual figure for FY2025 was 3084.18%, changed.
  • Return on Sales for Q2 2024 was 64.09% at Senti Biosciences, up from 16.8% in the prior quarter.
  • Over the last five years, Return on Sales for SNTI hit a ceiling of 64.18% in Q3 2023 and a floor of 144.83% in Q4 2022.
  • Median Return on Sales over the past 4 years was 6.47% (2023), compared with a mean of 5.56%.
  • Biggest five-year swings in Return on Sales: plummeted -13289bps in 2022 and later surged 15017bps in 2023.
  • Senti Biosciences' Return on Sales stood at 11.94% in 2021, then plummeted by -1113bps to 144.83% in 2022, then skyrocketed by 104bps to 5.34% in 2023, then skyrocketed by 1100bps to 64.09% in 2024.
  • The last three reported values for Return on Sales were 64.09% (Q2 2024), 16.8% (Q1 2024), and 5.34% (Q4 2023) per Business Quant data.